186 related articles for article (PubMed ID: 32354795)
1. Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma.
Shinmura H; Yoneyama K; Harigane E; Tsunoda Y; Fukami T; Matsushima T; Takeshita T
Int J Gynecol Cancer; 2020 Jun; 30(6):831-836. PubMed ID: 32354795
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
Kataoka T; Watanabe Y; Hoshiai H
J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
4. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer.
Li M; Tan J; Zhang Y; Ai C; Wang H; Zhang H; Jin Y; Chen Y
Abdom Radiol (NY); 2021 Jun; 46(6):2367-2375. PubMed ID: 32424610
[TBL] [Abstract][Full Text] [Related]
5. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
[TBL] [Abstract][Full Text] [Related]
6. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
8. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for the presence of malignant transformation of pelvic endometriosis.
Kadan Y; Fiascone S; McCourt C; Raker C; Granai CO; Steinhoff M; Moore RG
Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():23-7. PubMed ID: 25522113
[TBL] [Abstract][Full Text] [Related]
10. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
11. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors.
Lertkhachonsuk AA; Buranawongtrakoon S; Lekskul N; Rermluk N; Wee-Stekly WW; Charakorn C
J Obstet Gynaecol Res; 2020 Nov; 46(11):2287-2291. PubMed ID: 32830422
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
14. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
15. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms.
Magalhães JS; Jammal MP; Crispim PCA; Murta EFC; Nomelini RS
Biomarkers; 2021 May; 26(3):268-274. PubMed ID: 33554683
[TBL] [Abstract][Full Text] [Related]
16. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
17. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
18. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels.
Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H
J Gastroenterol; 2001 Mar; 36(3):166-72. PubMed ID: 11291879
[TBL] [Abstract][Full Text] [Related]
19. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and serum CA19-9 combined with HE4 are valuable in diagnosing endometriosis-associated ovarian cancer.
Xu T; Zhang L; Jiang Y; Wan Y; Zhou S; Sun G; Cheng W; Yuan L
Int J Gynaecol Obstet; 2023 Aug; 162(2):472-478. PubMed ID: 36708088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
